Welcome to the TriologieGroup

We are an association of highly specialized companies in the field of clinical development. We provide tailored and customized solutions, offering an outstanding standard of quality.

Our extensive range of services covers a wide spectrum, from comprehensive support in establishing your company up to the development and implementation of long-term strategic plans. We understand the unique requirements of each company and therefore offer flexible and adaptable services.

Our team comprises highly qualified professionals with extensive experience. We do not just deliver a solution but also offer a partnership based on trust.

We take pride in our ability to provide turn-key solutions to our clients and to seamlessly integrate into your existing operations. Our aim is to allow you to focus on your core business by providing excellence support for your clinical development projects.

Through ongoing research and development, we stay abreast of the latest technology and regulatory requirements. This enables us to offer innovative solutions that meet the ever-changing demands.

We are a trusted partner dedicated to your success and your targets.

 

News

ICH-E6(R3) Training by InnovationTriologie

ICH-E6(R3) Training by InnovationTriologie

June 04, 2025

The InnovationTriologie have recently completed a hybrid training program—combining web-based and face-to-face learning—on the current ICH-GCP E6(R3) guideline at Staburo GmbH in Munich. This comprehensive initiative has successfully trained more than 80 participants, equipping them with the essential knowledge and practical insights to implement the new Good Clinical Practice (GCP) guideline in the daily routines. Link: Staburo At ICH E6 (R3) Training  | Data science, biostatistics, data transparency, bioinformatics and statistical programming

The feedback has been very positive:
Participants engaged deeply with the material, appreciated the interactive format, and highlighted the relevance of the content to their day-to-day work in clinical research. We, at InnovationTriologie, are highly motivated by the positive feedback and are already looking forward to offering the next round of training.

Get Ready for July 2025

As a reminder, the new ICH-GCP E6(R3) guideline will become mandatory in the EU starting 23 July 2025. This shift brings important updates in quality- and risk management, data governance, and trial oversight—making preparation not just beneficial but essential.

InnovationTriologie is here to support organizations and professionals in understanding and applying these new standards. Whether you're an individual seeking to stay ahead or a company aiming to upskill your teams—we're ready to help you make the transition confidently.

📩 Reach out to us to learn more about our ACTA Education training options at training(at)triologie.org

Artificial Intelligence in Risk Management of Clinical Trials – Opportunities and Challenges under ICH E6(R3)

Artificial Intelligence in Risk Management of Clinical Trials – Opportunities and Challenges under ICH E6(R3)

May 30, 2025

With the release of the new ICH/GCP guideline ICH E6(R3) on 06-Jan-2025, continuous risk management in clinical trials has moved further into the spotlight. In this context, the use of Artificial Intelligence (AI) opens up new opportunities to meet the growing regulatory demands.

Helge Bonaventura and Dr. Andreas Berk described practical AI use cases that can enhance efficiency and mitigate risks in clinical research in a paper, that was published in the PM/QM journal by DGPharMed and German Quality Management Association e.V. In the article “Application of Artificial Intelligence in Risk Management of Clinical Trials” both aspects are addressed, the potential and the challenges of these technologies within the regulatory framework of ICH E6(R3).

The content of this article, which was also presented at the annual congress of DGPharMed 2025, reflects our ongoing commitment to innovation in clinical research and our efforts to improve the quality and safety of clinical trials by using AI tools and methods.

Download the full article as a PDF here: t3://file?uid=136

Artificial Intelligence in Clinical Development: Opportunities and Boundaries

Artificial Intelligence in Clinical Development: Opportunities and Boundaries

April 11, 2025

In the latest issue of pharmind (3/2025), Dr. Andreas Berk and Dr. Matthias Klüglich explore the growing role of Artificial Intelligence (AI) in Clinical Development. The article highlights current applications such as AI-assisted report generation, optimization of inclusion criteria, and automated quality control processes.

Both authors provide a balanced perspective, acknowledging the transformative potential of AI while emphasizing the importance of critically assessing its limitations and ethical implications. As the technology evolves rapidly, Dr. Matthias Klüglich and Dr. Andreas Berk call for ongoing evaluation to ensure responsible and effective integration into Clinical Research.

Knowledge Exchange and Support for Children's Hospice

Knowledge Exchange and Support for Children's Hospice

March 14, 2025

The role of Artificial Intelligence in Clinical Development was the central focus of a prestigious event held at the German Museum of Technology in Berlin. Initiated and supported by EventTriologie, the event brought together leading experts from Pharma and Industry to generate innovative impulses in Clinical Development. 

Instead of admission fees, donations were collected. A donation check of EUR 5,000 was presented to the Sonnenhof Children's Hospice in Berlin. The management and employees of BusinessTriologie were not just guests at this event – part of the donation was made possible by the entire BusinessTriologie team.

Knowledge Management

Knowledge Management

February 24, 2025

InnovationTriologie is proud to take responsibility for a comprehensive training concept. In today's clinical development environment, knowledge management has become an increasingly important factor. We are pleased to be able to provide a meaningful support to our customer.

EUCROF25

EUCROF25

February 03, 2025

Participants from InnovationTriologie attended the EUCROF25 congress in Copenhagen. The congress was meticulously designed to address the multifaceted nature of clinical research, covering essential topics such as regulatory changes, clinical trial technologies, quality assurance, data management and patient-centric approaches. The exchange with counterparts at European level was very helpful and provided new impulses.

REPEAT BUSINESS INNOVATIONTRIOLOGIE

REPEAT BUSINESS INNOVATIONTRIOLOGIE

January 20, 2025

In its 14th year, the Triologie Group continues to prioritize customer satisfaction as its core value. Our collaboration thrives on a commitment to excellence and a shared passion for achieving mutual project goals,

all within the complex framework of cost constraints and regulatory requirements in drug development. The trust shown by repeat business in 2025 serves as a powerful motivator for our entire team.

SLOGAN

SLOGAN

December 15, 2024

In 2025, we will embrace the theme of "STAYING TOGETHER," our vision aligned with the strategic decisions made by our leadership.

Expansion in Management

Expansion in Management

July 01, 2024

Effective July 1st, the executive team of BusinessTriologie expands as the new Chief Operating Officer assumes his position, enhancing our leadership. We warmly welcome Robert Kindervater and wish him great success in his new position.

Expansion in Management

Expansion in Management

July 01, 2024

Effective July 1st, the executive team of InnovationTriologie expands as the new Chief Operating Officer assumes his position, enhancing our leadership. We warmly welcome Dr. Andreas Berk and wish him great success in his new position.

 

Participation in DGPharMed congress

Participation in DGPharMed congress

April 19, 2024

We were represented at this year's DGPharMed congress on April 18th and 19th, 2024, in Mainz with two of our own exhibition stands. Detailed explanations and insights into our wide range of services, successful consultations, and information about our training academy ACTA were eagerly sought after. We are very pleased with the numerous interested parties and positive feedback that we were able to record.

Expert discussion "AI in drug development"

Expert discussion "AI in drug development"

March 21, 2024

On March 21st, 2024  an expert discussion by InnovationTriologie on the topic “AI in drug development” took place in Berlin. Three engaging keynote speeches shed light on the development and application possibilities of artificial intelligence from various perspectives. This was followed by a discussion round that promoted interdisciplinary exchange. The event provided valuable insights and highlighted the importance of this topic for science, business, and society. 

Fundraising Campaign

Fundraising Campaign

March 21, 2024

Supporting the Sonnenhof children's hospice in Berlin (Björn Schulz Stiftung (bjoern-schulz-stiftung.de) is a personal endeavor for all of us. Our donation helps to improving the lives of children with life-limiting illnesses and to support their families in difficult circumstances.

Repeat Business InnovationTriologie

Repeat Business InnovationTriologie

February 01, 2024

Auch im 12. Jahr des Bestehens der Triologie-Unternehmensgruppe steht die Kundenzufriedenheit an erster Stelle. Einsatz und Freude an gemeinsamen Projektzielen unter den Kostenzwängen und der Regelungsdichte in der Arzneimittelentwicklung zeichnen diese Zusammenarbeit aus. Neue Projekte in den Bereichen Quality Management, Project Coaching und Wissensmanagement für unsere Kunden sind Motivation und Ansporn zugleich.

Nachhaltigkeit in der TriologieUnternehmensgruppe

Nachhaltigkeit in der TriologieUnternehmensgruppe

January 10, 2024

Nachhaltigkeit ist ein äußerst wichtiges Thema und ein zentrales Anliegen der gesamten Triologie Unternehmensgruppe. Eine Vielzahl von Maßnahmen wurden bereits vor 12 Jahren auf ein belastbares Fundament gestellt. Von der Entscheidung für ein umweltfreundliches Home-Office-Modell bis hin zur E-Mobility-Strategie übernimmt das „Team in Orange“ soziale Verantwortung.

Zum Jahresanfang

Zum Jahresanfang

January 01, 2024

Die gesamte TriologieUnternehmensgruppe wünscht allen Geschäftspartnern und ihren Familien ein gesundes und erfolgreiches Jahr 2024.

Triologie Group Season’s Greetings

Triologie Group Season’s Greetings

December 20, 2024